|
Market Closed -
Nasdaq
16:00:00 2026-09-10 EDT
|
5-day change | 1st Jan Change | ||
| 55.16 USD | -0.97% |
|
-4.00% | +13.78% |
| 07-13 | GSK posts encouraging data for bowel cancer treatment Jemperli | AN |
| 06-29 | AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell 3000E Growth Benchmark | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- ANAB Stock
- Consensus AnaptysBio, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
